|
|
|
The BCR-ABL oncogene has for long been known to be a central player in the pathogenesis of chronic myeloid leukemia (CML). In the November 15th issue of Blood, researchers from UK have now demonstrated cell surface HLA-associated expression of a BCR-ABL oncogenic peptide. A cytotoxic T-lymphocyte response to the peptide was also shown to kill autologous CML cells, allowing Dr. Robert C. Rees of Nottingham Trent University and his colleagues to speculate that this observation may represent the first major step in the development of a vaccine against leukemia.
Contact :
Robert C. Rees
Department of Life Sciences
Nottingham Trent University
Nottingham NG11 8NS, UK
E-mail: robert.rees@ntu.ac.uk
Message posted by: Ulrike Sattler
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|